IND Today News DeskJan 20, 2025 Hyderabad, Jan 20 (Maxim News): A 57-year-old news reporter from a vernacular news channel, K. Ramesh, who was injured in a road crash at SR Nagar, died while undergoing treatment at a city hospital on Monday. ...
Instagram Twitter Spotify Out Now Riverhouse Indii G. Out Now Summer Nights Indii G. Out Now Hampton Indii G. Artist Bio Indii G. A modest rapper on the rise, citing collabs with Powfu and Sadboyprolific Indii G. started making music as a diary, putting his feelings into fruit … ...
6,175 Views +9 -1 Add to favorites *MY PLAYLIST* +9-1 Share this with your friends via: Ind 24 is an Hindi-language 24/7 News television channel, owned by Ind 24 Group Asia Limted Noida. Category:India Tags:English,Hindi,Ind 24,Ind 24 Online,News ...
GLOW试验证明在无进展生存期(PFS)方面,与安慰剂联合CAPOX组相比,zolbetuximab与CAPOX的联合用药组实现了统计学意义的显著提升。SPOTLIGHT试验证明,与安慰剂+mFOLFOX6相比,zolbetuximab+mFOLFOX6治疗的患者的PFS具有统计学意义;此外,该研究还满足了次要终点,即与安慰剂+ mFOLFOX6相比,zolbetuximab + mFOLFOX6治疗的...
24 09 2024 Essays/News ROOTS at 3Sat TV (Germany, Switzerland, Austria) and at the Austrian TV ORF The exhibition at the KBHG in Basel and the film are the subject of this report by the Austrian television channel ORF and by 3Sat Kulturzeit (in German): https://on.orf.at/video/...
9月6日,安进的maridebart cafraglutide 的IND 获CDE受理。Maridebartcafraglutide (AMG133)是一款first-in-class的双特异性抗体多肽偶联物,与礼来的GLP-1R/GIPR双靶点激动剂不同,AMG133激活GLP-1R但抑制GIPR,每4周皮下注射1次用于治疗肥胖。功能基因组学数据表明,GIPR表达下调与BMI下降相关,因此抑制GIPR可能是...
Denver, Colorado news, weather, traffic and sports. FOX31 KDVR & Colorado's Own Channel 2 KWGN covers Aurora, Lakewood, Thorton, Arvada and more.
6月8日,贝达药业的伏罗尼布片获NMPA批准,与依维莫司联合,用于既往接受过酪氨酸激酶抑制剂(TKI)治疗失败的晚期肾细胞癌患者。伏罗尼布是一种高效的VEGFR/ PDGFR酪氨酸激酶抑制剂,贝达药业全资子公司卡南吉医药拥有伏罗尼布全部适应症的中国权益,控股子公司Equinox拥有伏罗尼布眼科适应症的海外权益,通过控股子公司Xcovery拥有...
10月18日,国家药品监督管理局药品审评中心(CDE)官网显示,上海本导基因技术有限公司(简称“本导基因”)提交的BD211自体CD34+造血干细胞注射液临床试验申请获得受理。 资料显示,本导基因专注于体内基因编辑治疗为特色的基因治疗创新药物研发,致力于眼科、神经系统、造血系统、病毒感染以及肿瘤等多领域的难治性疾病药物开...
6、汇宇制药:HYP-2090PTSA胶囊 作用机制:靶向KRAS G12C/PI3K小分子抑制剂 适应症:实体瘤 7月19日,汇宇制药的HYP-2090PTSA胶囊的IND获CDE受理。HYP-2090PTSA是公司自主研发的KRASG12C/PI3K双靶点小分子抑制剂,临床前研究表明,HYP-2090PTSA可同时抑制KRASG12C和PI3K,双重阻断KRASG12C和PI3K介导的下游信号通路,实...